TL1A Transgenic Mice for the Study of Inflammatory Bowel Disease (IBD) and Allergic-Type Immune Responses


TL1A is a TNF family cytokine that co-stimulates T-cell proliferation and cytokine production through its interactions with the TNF family receptor DR3. TL1A-DR3 interactions have been shown to be important for the development of autoimmune inflammatory diseases, including inflammatory bowel disease (IBD).

In order to probe the role of TL1A-DR3 interactions in IBD, NIAMS inventors have developed transgenic mice that constitutively express TL1A in T cells or in dendritic cells. These mice spontaneously develop inflammatory small bowel pathology that is IL-13 dependent, and that closely resembles intestinal responses to allergens and to nematode infection.

These mice represent a unique model for the study of IBD, and in particular, the role of IL-13 in the development of this disease. They may also be used as a platform for investigating agents that block TL1A-DR3 interactions and the pathology associated with chronic TL1A expression.



Potential Commercial Applications: Competitive Advantages:
  • Studies of small bowel inflammation/IBD
  • Studies of the role of TL1A-DR3 interactions in the development of autoimmune inflammatory disease
  • Investigation of TL1A-DR3 blocking agents for the treatment of IBD or other TL1A-DR3 dependent diseases
 
  • Lines available with transgene expressed in T cells (under CD2 promoter) or dendritic cells (CD11c promoter)
  • Models are IL-13 dependent
  • No major defects in systemic immunity


Development Stage:

In vivo data available (animal)



Related Invention(s):
E-011-2007-0
E-073-2011-0


Inventors:

Richard Siegel (NIAMS)  ➽ more inventions...

Francoise Meylan (NIAMS)  ➽ more inventions...


Intellectual Property:
Research Tool — Patent protection is not being pursued for this technology.

Publications:

Meylan F, et al.

PMID 20980995

Meylan F, et al.

PMID 18571443

Collaboration Opportunity:

The National Institute of Arthritis and Musculoskeletal and Skin Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize TL1A Transgenic Mice. For collaboration opportunities, please contact Cecilia Pazman at pazmance@mail.nih.gov.




Licensing Contact:
Michael Shmilovich, J.D.
Email: shmilovm@mail.nih.gov
Phone: 301-435-5019

OTT Reference No: E-072-2011-0
Updated: Aug 30, 2011